Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIKFYVE | Q9Y2I7 | 5/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | BCR | P11274 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22024706 | 0.86 | PIKFYVE (0.78) | PIKFYVEABL1BCRRXFP1EGFR | |
| SCHEMBL22024636 | 0.85 | ABL1 (0.55) | PIKFYVEABL1BCRRXFP1EGFR | |
| SCHEMBL22024551 | 0.81 | PIKFYVE (0.88) | PIKFYVEABL1BCREGFRPDGFRB | |
| SCHEMBL22025017 | 0.80 | PIKFYVE (0.82) | PIKFYVEABL1BCREGFRPDGFRB | |
| SCHEMBL21943007 | 0.80 | PIKFYVE (0.61) | PIKFYVEABL1BCRRXFP1MEN1 | |
| SCHEMBL22024552 | 0.80 | PIKFYVE (0.74) | PIKFYVEABL1BCRRXFP1EGFR | |
| SCHEMBL22024870 | 0.79 | PIKFYVE (1.00) | PIKFYVEABL1BCREGFRPDGFRB | |
| SCHEMBL30675086 | 0.79 | PIKFYVE (1.00) | PIKFYVEABL1BCREGFRPDGFRB | |
| SCHEMBL22025016 | 0.78 | PIKFYVE (0.79) | PIKFYVEABL1BCREGFRPDGFRB | |
| SCHEMBL22024638 | 0.77 | RXFP1 (0.51) | ABL1BCRRXFP1EGFRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3663293-A1 | SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | Xiamen University (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | PIKFYVE 1/4885ABL1 1429/4885BCR 1416/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | PIKFYVE 1/4885ABL1 1429/4885BCR 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.